Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma in rats
- PMID: 28574023
- PMCID: PMC5460556
- DOI: 10.4103/ijmr.IJMR_542_14
Comparison of injectable doxorubicin & its nanodrug complex chemotherapy for the treatment of 4-nitroquinoline-1-oxide induced oral squamous cell carcinoma in rats
Abstract
Background & objectives: Combination treatments of chemotherapy and nanoparticle drug delivery have shown significant promise in cancer treatment. The aim of the present study was to compare the efficacy of a nanodrug complex with its free form in the treatment of tongue squamous cell carcinoma induced by 4-nitroquinoline-1-oxide in rats.
Methods: In this study, 75 male Sprague-Dawley rats were divided into five groups. Oral squamous cell carcinoma (OSCC) was induced by using 4- nitroquinoline-1-oxide (4NQO) as a carcinogen. Newly formulated doxorubicin (DOX)-methotrexate (MTX)-loaded nanoparticles, and free DOX-MTX were administrated intravenously to rats. During the study, the animals were weighed once a week. At the end of the treatment, rats' tongues were evaluated histopathologically.
Results: There was significant difference between the mean weight of rats in groups A and B (P=0.001) and also groups A and K (P<0.001). No significant association was found between the mortality rate of groups. The difference between the severity of dysplasia of treated and untreated groups was significant (P<0.001).
Interpretation & conclusions: Our study showed that DOX-MTX nanoparticle complex was more effective than free DOX-MTX in chemotherapy treatment of oral squamous cell carcinoma in rat models. Further investigations are necessary to clarify the advantages and disadvantages of the nanoparticle complex and its potential therapeutic application for different types of cancer.
Conflict of interest statement
Figures



Similar articles
-
Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: oral and IV modalities.Asian Pac J Cancer Prev. 2014;15(15):6227-32. doi: 10.7314/apjcp.2014.15.15.6227. Asian Pac J Cancer Prev. 2014. PMID: 25124602
-
Oral and IV dosages of doxorubicin-methotrexate loaded- nanoparticles inhibit progression of oral cancer by down- regulation of matrix Methaloproteinase 2 expression in vivo.Asian Pac J Cancer Prev. 2014;15(24):10705-11. doi: 10.7314/apjcp.2014.15.24.10705. Asian Pac J Cancer Prev. 2014. PMID: 25605162
-
DOX-MTX-NPs augment p53 mRNA expression in OSCC model in rat: effects of IV and oral routes.Asian Pac J Cancer Prev. 2014;15(19):8377-82. doi: 10.7314/apjcp.2014.15.19.8377. Asian Pac J Cancer Prev. 2014. PMID: 25339032
-
Nanoparticle-mediated active and passive drug targeting in oral squamous cell carcinoma: current trends and advances.Nanomedicine (Lond). 2023 Nov;18(27):2061-2080. doi: 10.2217/nnm-2023-0247. Epub 2024 Jan 10. Nanomedicine (Lond). 2023. PMID: 38197397 Review.
-
Understanding Nanotechnology in the Treatment of Oral Cancer: A Comprehensive Review.Crit Rev Ther Drug Carrier Syst. 2021;38(6):1-48. doi: 10.1615/CritRevTherDrugCarrierSyst.2021036437. Crit Rev Ther Drug Carrier Syst. 2021. PMID: 34587428 Review.
Cited by
-
Mouse Tumor-Bearing Models as Preclinical Study Platforms for Oral Squamous Cell Carcinoma.Front Oncol. 2020 Feb 25;10:212. doi: 10.3389/fonc.2020.00212. eCollection 2020. Front Oncol. 2020. PMID: 32158692 Free PMC article. Review.
-
Assessment of the Blood Parameters, Cardiac and Liver Enzymes in Oral Squamous Cell Carcinoma Following Treated with Injectable Doxorubicin-Loaded Nano-Particles.Asian Pac J Cancer Prev. 2019 Jul 1;20(7):1973-1977. doi: 10.31557/APJCP.2019.20.7.1973. Asian Pac J Cancer Prev. 2019. PMID: 31350953 Free PMC article.
References
-
- van der Waal I, de Bree R, Brakenhoff R, Coebergh JW. Early diagnosis in primary oral cancer: is it possible? Med Oral Patol Oral Cir Bucal. 2011;16:e300–5. - PubMed
-
- Masthan KMK, Babu NA, Dash KC, Elumalai M. Advanced diagnostic aids in oral cancer. Asian Pac J Cancer Prev. 2012;13:3573–6. - PubMed
-
- Scully C. Oral cancer aetiopathogenesis; past, present and future aspects. Med Oral Patol Oral Cir Bucal. 2011;16:e306–11. - PubMed
-
- Cheng YL, Wright J. Advances in diagnostic adjuncts for oral squamous cell carcinoma. Open Pathol. 2011;5:3–7.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical